JP2012530705A5 - - Google Patents

Download PDF

Info

Publication number
JP2012530705A5
JP2012530705A5 JP2012516178A JP2012516178A JP2012530705A5 JP 2012530705 A5 JP2012530705 A5 JP 2012530705A5 JP 2012516178 A JP2012516178 A JP 2012516178A JP 2012516178 A JP2012516178 A JP 2012516178A JP 2012530705 A5 JP2012530705 A5 JP 2012530705A5
Authority
JP
Japan
Prior art keywords
methyl
pharmaceutically acceptable
acceptable salt
trifluoromethyl
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012516178A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012530705A (ja
JP5596139B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/038568 external-priority patent/WO2010147917A1/en
Publication of JP2012530705A publication Critical patent/JP2012530705A/ja
Publication of JP2012530705A5 publication Critical patent/JP2012530705A5/ja
Application granted granted Critical
Publication of JP5596139B2 publication Critical patent/JP5596139B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012516178A 2009-06-19 2010-06-15 二置換フタラジンヘッジホッグ経路アンタゴニスト Active JP5596139B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21862809P 2009-06-19 2009-06-19
US61/218,628 2009-06-19
PCT/US2010/038568 WO2010147917A1 (en) 2009-06-19 2010-06-15 Disubstituted phthalazine hedgehog pathway antagonists

Publications (3)

Publication Number Publication Date
JP2012530705A JP2012530705A (ja) 2012-12-06
JP2012530705A5 true JP2012530705A5 (OSRAM) 2014-07-17
JP5596139B2 JP5596139B2 (ja) 2014-09-24

Family

ID=42332981

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012516178A Active JP5596139B2 (ja) 2009-06-19 2010-06-15 二置換フタラジンヘッジホッグ経路アンタゴニスト

Country Status (35)

Country Link
US (2) US8273742B2 (OSRAM)
EP (1) EP2443104B1 (OSRAM)
JP (1) JP5596139B2 (OSRAM)
KR (1) KR101389165B1 (OSRAM)
CN (1) CN102459233B (OSRAM)
AR (1) AR077014A1 (OSRAM)
AU (1) AU2010260244B2 (OSRAM)
BR (1) BRPI1011601A2 (OSRAM)
CA (1) CA2764542C (OSRAM)
CL (1) CL2011003147A1 (OSRAM)
CO (1) CO6480932A2 (OSRAM)
CR (1) CR20110658A (OSRAM)
DK (1) DK2443104T3 (OSRAM)
DO (1) DOP2011000386A (OSRAM)
EA (1) EA019059B1 (OSRAM)
EC (1) ECSP11011541A (OSRAM)
ES (1) ES2409054T3 (OSRAM)
HN (1) HN2011003139A (OSRAM)
HR (1) HRP20130408T1 (OSRAM)
IL (1) IL216599A (OSRAM)
JO (1) JO2931B1 (OSRAM)
MA (1) MA33363B1 (OSRAM)
MX (1) MX2011014029A (OSRAM)
MY (1) MY156667A (OSRAM)
NZ (1) NZ596882A (OSRAM)
PE (1) PE20121050A1 (OSRAM)
PL (1) PL2443104T3 (OSRAM)
PT (1) PT2443104E (OSRAM)
SG (1) SG177289A1 (OSRAM)
SI (1) SI2443104T1 (OSRAM)
TN (1) TN2011000627A1 (OSRAM)
TW (1) TWI385165B (OSRAM)
UA (1) UA106755C2 (OSRAM)
WO (1) WO2010147917A1 (OSRAM)
ZA (1) ZA201108587B (OSRAM)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2723042A1 (en) * 2008-04-29 2009-11-05 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
HRP20130527T1 (en) * 2008-11-03 2013-07-31 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
HRP20120762T1 (hr) 2008-11-17 2012-10-31 Eli Lilly And Company Tetrasupstituirani piridazini kao inhibitori hedgehog puta
ES2446307T3 (es) * 2008-11-17 2014-03-07 Eli Lilly And Company Piridazinas tetrasustituidas antagonistas de la ruta de Hedgehog
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
EP2688565A1 (en) 2011-03-23 2014-01-29 Semorex Technologies Ltd. Treatment of proliferative disorders with a chemiluminescent agent
GB201309508D0 (en) * 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
GB201311953D0 (en) * 2013-07-03 2013-08-14 Redx Pharma Ltd Compounds
WO2015073691A1 (en) 2013-11-14 2015-05-21 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating cancer by activation of bmp signaling
CN105017140B (zh) * 2014-04-28 2017-12-29 复旦大学 邻氨基苯甲酰胺化合物及其制备方法和用途
GB2528298A (en) * 2014-07-16 2016-01-20 Redx Pharma Plc Compounds
CN105985319B (zh) * 2015-02-11 2019-02-26 复旦大学 芳基酞嗪化合物及其制备方法和用途
CN105985320B (zh) * 2015-02-11 2018-10-26 复旦大学 苄基酞嗪化合物及其制备方法和用途
CN105985321B (zh) * 2015-02-11 2018-10-26 复旦大学 吡唑酞嗪化合物及其制备方法和用途
JP6796638B2 (ja) 2015-06-04 2020-12-09 ペレファーム, インク.Pellepharm, Inc. ヘッジホッグ阻害性化合物の送達のための局所的製剤及びその使用
AU2016271432A1 (en) * 2015-06-05 2017-12-07 Dana-Farber Cancer Institute, Inc. Compounds and methods for treating cancer
CN120661674A (zh) 2016-03-15 2025-09-19 奥莱松基因组股份有限公司 用于治疗实体瘤的lsd1抑制剂的组合
CN106279114B (zh) * 2016-08-04 2019-01-29 东南大学 一种Taladegib的合成方法
US10548908B2 (en) 2016-09-15 2020-02-04 Nostopharma, LLC Compositions and methods for preventing and treating heterotopic ossification and pathologic calcification
CN106831718B (zh) * 2016-12-30 2019-05-07 上海科技大学 平滑受体配体及其应用
EP3624798A1 (en) 2017-05-18 2020-03-25 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods and pharmaceutical compositions for the treatment of mast cell diseases
US20230301950A1 (en) 2020-06-26 2023-09-28 Raqualia Pharma Inc. Method for selecting cancer patients for whom combination therapy with retinoid and cancer therapeutic agent is effective, and combination medicament with retinoid and cancer therapeutic agent
CA3198661A1 (en) 2020-10-13 2022-04-21 Endeavor Biomedicines, Inc. Methods of treating fibrosis
US12447148B2 (en) 2024-03-05 2025-10-21 Endeavor Biomedicines, Inc. Methods of improving lung function
WO2025189041A1 (en) * 2024-03-07 2025-09-12 Endeavor Biomedicines, Inc. Methods of treating fibrosis
WO2025242197A1 (zh) * 2024-05-24 2025-11-27 成都思倍博医药科技有限公司 氘代的Hedgehog通路SMO受体抑制剂

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN148482B (OSRAM) 1977-06-03 1981-03-07 Pfizer
JP4169368B2 (ja) 1996-01-15 2008-10-22 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 脈管形成阻害性ピリダジンアミン
EP1067939B1 (en) 1998-04-09 2015-09-16 The Johns Hopkins University Use of steroidal alkaloid derivatives as inhibitors of hedgehog protein signaling pathways
JP2003501395A (ja) 1999-06-08 2003-01-14 ローランティス・リミテッド 治療的使用
NZ530580A (en) * 2001-07-27 2007-02-23 Curis Inc Mediators of hedgehog signaling pathways, compositions and uses related thereto
CA2483311A1 (en) * 2002-04-22 2003-10-30 Philip A. Beachy Modulators of hedgehog signaling pathways, compositions and uses related thereto
AU2003265853A1 (en) 2002-08-29 2004-03-19 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
WO2005033288A2 (en) 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
WO2005080378A1 (ja) 2004-02-24 2005-09-01 Mitsubishi Pharma Corporation 縮合ピリダジン誘導体
WO2006004589A2 (en) 2004-05-08 2006-01-12 Neurogen Corporation 3-aryl-5,6-disubstituted pyridazines
PT1789390E (pt) 2004-09-02 2012-02-08 Genentech Inc Inibidores de piridilo da sinalização de hedgehog
EP1900731A1 (de) * 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
SG182205A1 (en) * 2007-03-15 2012-07-30 Novartis Ag Organic compounds and their uses
WO2009002469A1 (en) * 2007-06-25 2008-12-31 Amgen Inc. Phthalazine compounds, compositions and methods of use
AU2008300019A1 (en) 2007-09-07 2009-03-19 Amgen Inc. Annelated pyridazines for the treatment of tumors driven by inappropriate hedgehog signalling
EP2227456A2 (en) * 2007-12-13 2010-09-15 Siena Biotech S.p.A. Hedgehog pathway antagonists and therapeutic applications thereof
CA2723042A1 (en) 2008-04-29 2009-11-05 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
AU2009279760B2 (en) * 2008-08-04 2012-07-12 Amgen Inc. Aurora kinase modulators and methods of use
HRP20130527T1 (en) 2008-11-03 2013-07-31 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
HRP20120762T1 (hr) 2008-11-17 2012-10-31 Eli Lilly And Company Tetrasupstituirani piridazini kao inhibitori hedgehog puta
ES2446307T3 (es) 2008-11-17 2014-03-07 Eli Lilly And Company Piridazinas tetrasustituidas antagonistas de la ruta de Hedgehog
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer

Similar Documents

Publication Publication Date Title
JP2012530705A5 (OSRAM)
JP2012507535A5 (OSRAM)
JP2010523692A5 (OSRAM)
JP2011527666A5 (OSRAM)
JP2017504611A5 (OSRAM)
JP2015508749A5 (OSRAM)
JP2014515013A5 (OSRAM)
JP2014504646A5 (OSRAM)
JP2009535462A5 (OSRAM)
JP2014507464A5 (OSRAM)
JP2010536766A5 (OSRAM)
JP2015180703A5 (OSRAM)
JP2013505969A5 (OSRAM)
JP2014508811A5 (OSRAM)
JP2009545527A5 (OSRAM)
JP2013531028A5 (OSRAM)
JP2011519854A5 (OSRAM)
IL202018A (en) 4,2-Difluoro-n- {2- (Methylaoxy) -5- [4- (4-Pyridazinyl) -6-Quinolinyl] -3-Pyridinyl} Benzenesulfonamide, its Pharmaceuticals and Its Use in the Treatment of Pi3 Kinase-Related Diseases
JP2011500550A5 (OSRAM)
JP2015524472A5 (OSRAM)
JP2013523733A5 (OSRAM)
JP2014528403A5 (OSRAM)
JP2015501799A5 (OSRAM)
JP2011246469A5 (OSRAM)
JP2017517538A5 (OSRAM)